Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Beule, Dieter Dr. (1) Bunse, Mario Dr. (1) Edes, Inan Dr. (1) Gavvovidis, Ioannis Dr. (1) Gerhardt, Holger Prof. Dr. (1) Hübner, Norbert Prof. Dr. (1) Kammertöns, Thomas Dr. (2) Kettenmann, Helmut Prof. Dr. (1) Kunz, Severine Dr. (1) Lorenz, Felix Dr. (2) Patone, Giannino Dr. (1) Szymborska-Mell, Anna Bozena Dr. (1) Uckert, Wolfgang Prof. Dr. (27) Willimsky, Gerald Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (6) (-) Leisegang, Matthias Dr. (13) (-) Obenaus, Matthias (1) 1998 (2) 2000 (2) 2003 (4) 2004 (1) 2005 (3) 2006 (2) 2007 (1) 2008 (2) (-) 2010 (4) (-) 2011 (2) (-) 2012 (3) 2014 (2) (-) 2015 (3) 2016 (2) (-) 2017 (2) 2018 (1) 2019 (1) Biology of Malignant Lymphomas (19) Cancer Genetics and Cellular Stress Responses (2) Genetics and Genomics of Cardiovascular Diseases (1) Immune Regulation and Cancer (1) Integrative Vascular Biology (1) (-) Molecular Cell Biology and Gene Therapy (14) Molecular Immunology and Gene Therapy (27) Molecular Immunotherapy (3) Systems Biology of Gene Regulatory Elements (1) 14 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Leisegang, Matthias Dr.Obenaus, MatthiasMolecular Cell Biology and Gene Therapy20102011201220152017 Sort: Result score Newest to oldest Oldest to newest July 01, 2017 in Canc Res Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy R. Schlenker L.F. Olguín-Contreras M. Leisegang J. Schnappinger A. Disovic S. Rühland P.J. Nelson H. Leonhardt H. Harz S. Wilde D.J. Schendel W. Uckert G. Willimsky E. Noessner May 04, 2017 in Nature Tumour ischaemia by interferon-γ resembles physiological blood vessel regression T. Kammertoens C. Friese A. Arina C. Idel D. Briesemeister M. Rothe A. Ivanov A. Szymborska G. Patone S. Kunz D. Sommermeyer B. Engels M. Leisegang A. Textor H.J. Fehling M. Fruttiger M. Lohoff A. Herrmann H. Yu R. Weichselbaum W. Uckert N. Hübner H. Gerhardt D. Beule H. Schreiber T. Blankenstein June 01, 2015 in BIOspektrum Designer T cells - New possibilities for immunotherapy of cancer [Designer-T-Zellen - neue Möglichkeiten für die Immuntherapie von Krebs] M. Leisegang W. Uckert April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein October 01, 2012 in J Virol Protective capacity of virus-specific T cell receptor (TCR)-transduced CD8 T cells in vivo K. Mueller A. von Maessenhausen U. Aichele L. Staerck M. Leisegang W. Uckert H. Pircher July 15, 2012 in J Immunol Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition S. Wilde D. Sommermeyer M. Leisegang B. Frankenberger B. Mosetter W. Uckert D.J. Schendel April 12, 2012 in Blood TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo S. Spranger I. Jeremias S. Wilde M. Leisegang L. Staerck B. Mosetter W. Uckert M.H.M. Heemskerk D.J. Schendel B. Frankenberger July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens Pagination Current page 1 Page 2 Next page Next › Last page Last »
July 01, 2017 in Canc Res Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy R. Schlenker L.F. Olguín-Contreras M. Leisegang J. Schnappinger A. Disovic S. Rühland P.J. Nelson H. Leonhardt H. Harz S. Wilde D.J. Schendel W. Uckert G. Willimsky E. Noessner
May 04, 2017 in Nature Tumour ischaemia by interferon-γ resembles physiological blood vessel regression T. Kammertoens C. Friese A. Arina C. Idel D. Briesemeister M. Rothe A. Ivanov A. Szymborska G. Patone S. Kunz D. Sommermeyer B. Engels M. Leisegang A. Textor H.J. Fehling M. Fruttiger M. Lohoff A. Herrmann H. Yu R. Weichselbaum W. Uckert N. Hübner H. Gerhardt D. Beule H. Schreiber T. Blankenstein
June 01, 2015 in BIOspektrum Designer T cells - New possibilities for immunotherapy of cancer [Designer-T-Zellen - neue Möglichkeiten für die Immuntherapie von Krebs] M. Leisegang W. Uckert
April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
October 01, 2012 in J Virol Protective capacity of virus-specific T cell receptor (TCR)-transduced CD8 T cells in vivo K. Mueller A. von Maessenhausen U. Aichele L. Staerck M. Leisegang W. Uckert H. Pircher
July 15, 2012 in J Immunol Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition S. Wilde D. Sommermeyer M. Leisegang B. Frankenberger B. Mosetter W. Uckert D.J. Schendel
April 12, 2012 in Blood TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo S. Spranger I. Jeremias S. Wilde M. Leisegang L. Staerck B. Mosetter W. Uckert M.H.M. Heemskerk D.J. Schendel B. Frankenberger
July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
